How many insider trades does FilingIQ track for LCTX?

FilingIQ tracks 102 Form 4 insider transactions for LCTX (Lineage Cell Therapeutics, Inc.), covering filings from Aug 13, 2019 onwards. 3 of those were filed in the last 90 days.

Are LCTX insiders net buyers or net sellers?

Across the full Form 4 history for LCTX, 32 transactions (31%) were open-market purchases and 7 (7%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does LCTX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is LCTX in?

Lineage Cell Therapeutics, Inc. (LCTX) is classified in the Financial Services sector, specifically Asset Management, with a current market capitalisation of $1.40B.

LCTX insider trading

NYSE Financial Services

Lineage Cell Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

102

Last 90 days

Buys / sells

31% / 7%

Market cap

$1.40B

About Lineage Cell Therapeutics, Inc.

BlackRock Technology and Private Equity Term Trust is a mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. BlackRock Technology and Private Equity Term Trust is domiciled in the United States.

LCTX insider activity at a glance

FilingIQ has scored 102 insider transactions for LCTX since Aug 13, 2019. The most recent filing in our index is dated Mar 12, 2026.

Across the full history, 32 open-market purchases and 7 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on LCTX insider trades is 60.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live LCTX trades on FilingIQ Raw filings on SEC EDGAR

Latest LCTX Form 4 filings

Culley Brian M President and CEO

P Nov 21, 2024

Howe Jill Ann Chief Financial Officer

P Aug 16, 2024

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Financial Services tickers with recent insider activity

BAC 353

BANK OF AMERICA CORP /DE/

RCG 255

RENN Fund, Inc.

WAL 242

WESTERN ALLIANCE BANCORPORATION

CINF 239

CINCINNATI FINANCIAL CORP

CRCL 178

Circle Internet Group, Inc.

TRUP 156

TRUPANION, INC.

PGC 154

PEAPACK GLADSTONE FINANCIAL CORP

SLDE 150

Slide Insurance Holdings, Inc.

Frequently asked

How many insider trades does FilingIQ track for LCTX?: FilingIQ tracks 102 Form 4 insider transactions for LCTX (Lineage Cell Therapeutics, Inc.), covering filings from Aug 13, 2019 onwards. 3 of those were filed in the last 90 days.
Are LCTX insiders net buyers or net sellers?: Across the full Form 4 history for LCTX, 32 transactions (31%) were open-market purchases and 7 (7%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does LCTX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is LCTX in?: Lineage Cell Therapeutics, Inc. (LCTX) is classified in the Financial Services sector, specifically Asset Management, with a current market capitalisation of $1.40B.

Methodology & sources

Every LCTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.